永安藥業(002365.SZ)業績快報:2019年度淨利潤降50.29%至8876.6萬元
格隆匯2月28日丨永安藥業(002365.SZ)披露2019年度業績快報,實現營業總收入13.70億元,同比增長36.31%;營業利潤1.16億元,同比下降45.43%;利潤總額1.16億元,同比下降45.42%;歸屬於上市公司股東的淨利潤8876.6萬元,同比下降50.29%;基本每股收益0.3029元。
上述幾個與利潤相關指標變動的主要原因系報告期牛磺酸銷量下滑,價格回落,毛利率下降所致。
2019年度,牛磺酸經營面臨的不利因素較多,競爭加劇,導致銷量下滑,價格回落,產品利潤有所下降;而得益於2018年底收購併控股凌安科技,環氧乙烷裝置全年平穩運行,實現了大幅度的減虧,凌安科技擴建項目順利完成並得到進一步發展,其盈利能力增強,為公司的收入和利潤帶來一定的貢獻;子公司永安康健加強保健產品營銷,銷售收入增長較快。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.